# Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

> **NCT03255018** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Lymphoma
- Diffuse Large B-Cell Lymphoma
- Gray-zone Lymphoma
- Primary Central Nervous System Lymphoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03255018
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-15
- **Primary completion:** 2022-10-22
- **Final completion:** 2023-06-29
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255018, "Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03255018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*